Acadia Healthcare's stock soared 5.85% during intraday trading on Monday, following a series of positive analyst actions.
Raymond James upgraded Acadia Healthcare to Strong Buy from Outperform and raised its price target to $39 from $25, representing a significant increase. Additionally, RBC Capital raised its price target on the stock to $31 from $28 while maintaining an Outperform rating. Guggenheim also maintained a Buy rating on the company.
These analyst upgrades and price target increases reflect growing optimism about Acadia Healthcare's prospects, driving investor confidence and buying activity in the stock.